ENO2 and prostate carcinoma: Neuroendocrine differentiation in prostate cancer typically involves the expression of markers like neuron-specific enolase (NES), chromogranin A (CHGA), P63, and CD56, and usually lacks androgen receptor (AR) expression (16, 17).